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Altered fractionationAbstract Introduction: Fractionation plays a pivotal role in determining the effectiveness of radi-
ation and follows the principle of 4 ‘‘R” of radiobiology. The various altered fractionation sched-
ules used are hyper-fractionation, accelerated fractionation, and hypo fractionation.
Methods: We reviewed the landmark articles published in the peer reviewed journals to summarize
the beneﬁcial role of altered fractionation in the treatment of head and neck carcinoma.
Results: Hyper-fractionation deﬁnitely gives very good overall survival beneﬁt for locally advanced
head and neck patient’s equivalent to survival beneﬁt to that of concurrent chemoradiotherapy.
Adding concomitant chemotherapy to altered fractionation is a logical approach to improve sur-
vival in locally advanced head and neck cancer patients, but it may be at a cost of higher toxicity.
Mild hypo fractionation may be beneﬁcial in early laryngeal cancers and may help in achieving bet-
ter local control.
Conclusion: Altered fractionation is a very important treatment schema and requires the reinforce-
ment of its use.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
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Head and neck squamous cell carcinoma (HNSCC) is a major
oncologic burden in developing countries (age standardized
rate of incidence of 10–30/100,000) [1]. In the developing coun-
tries 80% of these patients present with locally advanced stage
[2]. The treatment practice for this group of patients varies
from surgery followed by post-operative radiotherapy, radio-
chemotherapy, radical radiotherapy, induction chemotherapy
followed by concurrent chemo radiotherapy and recently
bio-radiotherapy. According to the recent evidences both
chemotherapy and radiotherapy should be used in combina-
tion for such cases. In the MACH-NC meta-analysis concur-
rent chemo-radiotherapy was found to be the most effective
approach with an absolute beneﬁt of 6.5% in 5 years [3]. But
the compliance and tolerance is a major concern with
chemoradiotherapy especially in developing countries [4].
Altered fractionation is a feasible option in these patients with
better safety proﬁle compared to chemoradiotherapy. In this
review we have focused on the altered fractionation schedule
radiotherapy alone or with combination with other agents.
Since 1895 when X-ray was invented by W C Roentgen,
radiation has been used for different malignant as well as
benign conditions. But the concept of fractionation was not
known. Thor Stenbeck (Stockholm, 1900) is credited to use
small doses of radiation given each day to cure skin cancer
[5]. This technique was subsequently called ‘fractionated radio-
therapy’. Later on Coutard showed that in cancers of pharynx
and larynx, protracted fractionation result in better skin and
mucosal tolerance, and improved tumor response [6]. Later
on with the understanding of radiobiology radiation practice
became more protracted and 1.8–2 Gy per fraction was found
to give good local control at low normal tissue complication
rates, and this practice was called conventional fractionated
radiotherapy. With better understanding of 4 Rs of radiobiol-
ogy the importance of different fractionation schedule came
into practice. The various altered fractionation schedules used
are hyper-fractionation, accelerated fractionation, hypo-
fractionation and a combination of these. A brief overview
of the various fractionation schedules is summarized in
Table 1.
Hyper-fractionation
In hyper-fractionation, radiation is delivered in small dose per
fraction with two or three fractions delivered per day to
achieve a higher biologically effective dose to the tumor when
the a/b ratio for tumor cells is greater than that for the dose-
limiting, late-responding normal tissue. Hyper fractionation
also induces radio-sensitization through cell-cycle redistribu-
tion. Reduction of the fraction size from 2.0 Gy to 1.1–
1.2 Gy permits a 7–17% escalation in total radiation-dosewithout leading to a detectable increase in late normal-tissue
injury. Two randomized control studies have evaluated the
hyper fractionation for locally advanced head and neck cancer.
RTOG 9003 was a four arm randomized controlled study that
used 81.6 Gy in 68 fraction at 1.2 Gy twice daily for 5 days per
week. Initial results of the study found increased local control
(p – 0.045), and a trend toward improving DFS (p – 0.067) but
there was no difference in Overall survival. Acute toxicity was
found to increase but did not reach statistical signiﬁcance [7].
The 5 year update of this study was published in 2014 which
showed that hyper-fractionated radiotherapy improved local
control and overall survival when compared to the conven-
tional radiotherapy arm without increasing late toxicity [8].
The hyper fractionated schedules tried by Cummings et al. also
found better tumor control at the cost of increased acute tox-
icity but late effects were not increased [9]. Of all the fraction-
ation schedules evaluated in the MARCH meta-analysis the
maximum beneﬁt in the form of overall survival was for
hyper-fractionation (8% at 5 years) [10]. A brief overview of
the various trails evaluating hyper-fractionation schedules is
summarized in Table 2.
Hyper-fractionation showed a deﬁnite trend to improve dis-
ease control and survival (OS-8% at 5 years) for locally
advanced head and neck patient’s equivalent or more com-
pared to survival beneﬁt achieved with concurrent chemora-
diotherapy (OS-6.5% at 5 years). But it is not widely
followed in head and neck protocols due to logistic reasons
in implementing the twice daily schedule. However, recently
different institutes are attempting to use hyper fractionation
with concurrent chemotherapy as well.Accelerated fractionation
From the understanding of radiobiology it was known that
after a certain period of radiotherapy known as lag phase
the resistant tumor clonogens start accelerated repopulation.
Therefore an incremental dose of 0.6 Gy is required after the
certain lag phase of 4 weeks to counter the accelerated repop-
ulation to achieve tumor control. The concept of accelerated
fractionation is to complete radiotherapy within 4 weeks so
as to overcome this accelerated repopulation. There are differ-
ent types of accelerated fraction schedules, the ﬁrst group, pure
accelerated fractionation regimens, reduce the overall treat-
ment time without concurrent changes in the fraction size or
total dose. But there are hybrid accelerated fractionation
schedules which reduce the overall treatment time with
changes in other variables such as fraction size, total dose,
and time distribution. Three types of hybrid accelerated frac-
tionations have been used Type A consists of an intensive short
course of treatment in which the overall duration is much
shortened with a substantial decrease in the total dose. In types
B and C, the duration of treatment is more modestly shortened
Table 1 Brief overview of the various fractionation schedules.
Type of fractionation Rationale Overall treatment time Dose per fraction Total dose Acute toxicity Late toxicity
Hyper fractionation Diﬀerence in rate of repair by
normal tissue and tumor
Same Generally 1.2–1.5 Gy/fraction Increased by
7–17%
Increased Reduced
Radiobiology: re-oxygenation,
re-distribution
Accelerated fractionation Counter accelerated repopulation Reduced 1.8–2 Gy/fraction Same or reduced Increased Same/increased
Radiobiology: repopulation
Hypo-fractionation Useful in tumors with low
alfa/beta and normal tissue with
high alfa/beta
Reduced >2.2 Gy/fraction Reduced Same Increased
In cases of palliation when long
term toxicity is not a concern
Radiobiology: repair, repopulation
Table 2 Summary of trials comparing conventional vs. hyper fractionation in head and neck malignancies.
Author/year Nature of trial Number of patients Outcome Toxicity
Bourhis/2006 Meta-analysis 6515 Absolute survival beneﬁt at 5 years –
MARCH metaanalysis
[10]
Hyper fractionated radiotherapy – 8%
Beitler/2014 Randomized 4
arm
1076 Survival beneﬁt with hyper fractionation No increase in late toxicity with hyper
fractionation compared to conventional
arm
RTOG 9003 [9] Study HR 0.81, P= .05
Budach/2006 [11] Meta-analysis 10,225 Substantial prolongation of median
survival (14.2 months, p< 0.001) was
seen for HFRT compared to CFRT
–
No signiﬁcant gain in overall survival was
observed for AFRT in comparison to
CFRT
Cummings/2006 [10] Randomized 2
arm study
331 5 year survival (40% vs. 30%) was also
improved with HF compared to CF arm
The HF arm had a greater proportion
acute toxicity of grade 3 or 4 toxicity
(70% vs 53%)
Grade 3 and 4 late toxicity for the CF was
10.5% compared to 7.7% in the higher
dose HF arm
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76 S. Mallick et al.but the total dose is kept in the same range as a conventional
treatment, by the use of either split-course twice-daily fraction-
ation (type B) or concomitant boost fractionation (type C).
In the largest trial of pure AF by Overgaard et al.
(DAHANCA 6&7study), which included 1476 patients who
were randomized either an accelerated regimen of six fractions
of radiotherapy per week or to receive a conventional radio-
therapy regimen of ﬁve fractions per week. the total dose
and fraction size were same in both arms 66–68 Gy in 33–34
fractions. The analysis showed 5-year LRC, 70% in acceler-
ated regimen vs. 60 % in conventional radiotherapy regimen
(p= 0.005); 5-year DFS, 73% in accelerated regimen vs.
66% in conventional radiotherapy regimen (p= 0.01); but
there was no difference in OS between the two arms [12].
In a similar trial by Overgaard et al. (IAEA-ACC study),
which included more than 900 patients who were randomized
either an accelerated regimen of six fractions of radiotherapy
per week or to receive a conventional radiotherapy regimen
of ﬁve fractions per week, the total dose was 66–70 Gy in
33–35 fractions. The analysis of data of his trial showed the
5-year loco-regional control was 42% in the accelerated group
versus 30% in the conventional group (hazard ratio
[p= 0004). Acute morbidity in the form of conﬂuent mucosi-
tis was higher in accelerated group. There were no signiﬁcant
differences in late side-effects between the two arms [13].
Accelerated fractionation radiotherapy (type A)
The prototype of this type is continuous hyper fractionated
accelerated radiotherapy (CHART). Skaldowski et al. evalu-
ated accelerated fractionation 7 days a week including week-
ends [continuous accelerated irradiation (CAIR)] and
conventional 5 days a week. Five-year local tumor control
was 75% in CAIR group and 33% in control arm
(p< 0.00004) [14]. Conﬂuent mucositis was signiﬁcantly high
in the CAIR group (94% vs. 53%). In a large randomized,
multi-center trial (n= 908), Overgaard et al. compared ﬁve
versus six fractions of radiotherapy per week for squamous-
cell carcinoma of the head and neck (IAEA-ACC study).
The authors reported excellent 92% compliance with both
treatment strategies. 5-year LRC, 42% vs 30% (p= 0.004);
5-year DFS, 50% vs 40% (P= 0.03); but no difference in
OS (35% vs. 28%, p= 0.07) [13]. Hence, the authors showed
the possibility of reducing overall treatment time with better
local control.
Accelerated fractionation with split-course (type b) or
concomitant boost (type c)
EORTC is a randomized controlled trial compared accelerated
fractionation (AF) with conventional fractionation (CF) [15].
This trial included all advanced head and neck cancers except
hypo pharynx with age < 75 years, WHO status 0, 1, 2 and
randomized to accelerated fractionation three fractions per
day at l.6 Gy per fraction. In the 1st course 28.8 Gy delivered
in 18 fractions in 8 days followed by 12–14 days split and then
2nd course of 43.2 Gy in 27 fractions over 17 days up to a total
dose of 72 Gy in 45 fractions over 5 weeks. At 5 years, the
loco-regional control gain was 13% (from 46% in the CF
arm to 59% in the AF arm; 95% CI 3–23% gain), representing
a 24% reduction of the local failure rate. In patients withunfavorable T and N (N2, N3 any T, T4 any N) the beneﬁt
in favor of the AF arm was statistically signiﬁcant
(P= 0.03) with 55% loco-regional control in the AF arm ver-
sus 37% in the CF arm (18% beneﬁt, 95% CI 3–33% beneﬁt).
The split course accelerated radiotherapy is no more prac-
ticed in head and neck cancers as it is radio biologically infe-
rior. The wide spread use of intensity modulated
radiotherapy helps radiation oncologist to deliver concomitant
boost to the tumor with very limited added toxicity and is
being evaluated in many trials.
A brief summary of the various trails evaluating accelerated
radiotherapy schedules in head and neck cancers is summa-
rized in Table 3.
Altered fractionation radiotherapy vs concurrent chemotherapy
The beneﬁt in altered fractionation led to many investigators
comparing concurrent chemoradiotherapy versus altered frac-
tionation. Chitapanarux et al. conducted a prospective ran-
domized clinical trial to compare chemoradiation vs.
accelerated hyper-fractionated radiotherapy on 85 patients
[17]. The results showed that the 5-year loco-regional control
rate was 69.6% in the chemoradiation arm vs. 55.0% in the
accelerated hyper-fractionation arm (P= 0.184). The 5-year
overall survival rate was 76.1% in the chemoradiation arm
vs. 63.5% in the accelerated hyper-fractionation arm
(P= 0.05).
Gupta et al. did a meta-analysis to compare the role of con-
comitant chemoradiotherapy versus altered fractionation
radiotherapy in loco regionally advanced head and neck carci-
noma [18]. In the meta-analysis he concluded that hyper-
fractionation was comparable to chemoradiotherapy in terms
of the hazard ratio [HR 1.13] for death. But accelerated radio-
therapy with or without dose reduction was inferior to
chemoradiotherapy in terms of hazard ratio for death.
In the MARCH meta-analysis it was seen that altered frac-
tionation had more pronounced effect on local control while
the effect was less pronounced in nodal control. Thus though
logistically challenging hyper-fractionated radiotherapy may
give similar results to that of concurrent chemoradiotherapy
and may be tried in of locally advanced head and neck cancers
if feasible. It may be also more useful in patients with limited
nodal burden. Accelerated radiotherapy may provide better
overall survival and local control than conventional radiother-
apy but the results are inferior to chemoradiotherapy. But
accelerated radiotherapy schedules are easier to implement
than hyper-fractionated scheduled and thus may be tried on
who may not be suitable for chemotherapy and in centers
where implementing hyper-fractionation is difﬁcult.
Altered fractionation radiotherapy with concurrent
chemotherapy or targeted therapy
The MACH NC meta-analysis concluded that the addition of
concurrent chemotherapy gives an impressive 6.5% absolute
overall survival advantage [3]. The MARCH meta-analysis
concluded 8% absolute overall survival beneﬁt of hyper frac-
tionation radiotherapy [10]. Many investigators tried to com-
bine these two modalities to achieve a better tumor control.
An Austrian trial compared the fractionation schedule of
553 Gy in 17 days given alone or plus concurrent Mitomycin
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Altered fractionation radiotherapy in Head and neck squamous cell carcinoma 77C with standard fractionation alone [19]. At median follow-up
of 48 months, local control and actuarial survival were signif-
icantly higher with the combined chemotherapy and altered
fractionation arm. A third of the patients treated with conven-
tional fractionation and nearly all those treated with acceler-
ated fractionation developed grade-III mucositis. A German
cooperative group compared a concomitant boost radiation
regimen alone with the same regimen plus carboplatin and ﬂu-
orouracil [20]. The investigators found better loco-regional
control rates and survival with the combined treatment. The
study also found a signiﬁcantly higher frequency of chronic
dysphagia resulting in feeding-tube dependency. RTOG 99-
14, a phase II study accrued 84 patients of oral cavity,
oropharynx, hypopharynx and larynx to concomitant boost
radiation (72 Gy in 6 weeks) plus concurrent cisplatin. The
authors reported 2 and 4 year loco regional failure of 33%
and 36%. 2 and 4 year overall survival 70% and 54% respec-
tively with 42% grade 3–4 late toxicity showing feasibility of
combining accelerated fractionation radiation and chemother-
apy [21]. Rishi et al. in a phase III trial allocated 216 patients
of stage III-IVA oropharyngeal cancer to receive either
chemoradiation to a dose of 66 Gy in 33 fractions over 6.5 weeks
or accelerated radiotherapy with concomitant boost to a dose of
67.5 Gy in 40 fractions over 5 weeks. The authors reported sim-
ilar disease control (at 2 years 56% vs. 61%) with more acute and
late toxicity in the chemoradiation arm. However, compliance to
radiotherapy was superior in concomitant boost with lesser treat-
ment interruptions [22]. Subsequently a large phase III random-
ized study, RTOG 0129, randomly allocated 723 patients of stage
III–IV (T2N2-3M0, T3-4 Any N M0, no T1-2N1 or T1N2-3)
oral cavity, oropharynx, hypopharynx, or larynx to either con-
ventional chemo-radiation 70 Gy in 35 fractions over 7 weeks
or concomitant boost chemo-radiation 72 Gy in 42 fractions in
6 weeks. In an updated analysis with a median follow up of
7.9 years the trial reported no differences in overall survival, pro-
gression free survival, loco regional failure and distant metastasis
rate. There were no statistically signiﬁcant differences in the
grade 3–5 acute or late toxicities between the two arms [23]. In
another phase III trial 891 patients of locally advanced larynx,
oropharynx and hypopharynx were randomly allocated to
receive radiation and cisplatin without (arm A) or with (arm B)
Cetuximab. Radiation regimens included 72 Gy in 42 fractions
over 6 weeks, using concomitant boost or 70 Gy in 35 fractions
over 6 weeks. This trial failed to ﬁnd advantage of adding Cetux-
imab to the cisplatin based chemoradiation schedule [24]. There-
fore, point should be made that the addition of chemotherapy or
targeted therapy is feasible but it failed to improve outcome. This
may be explained by the increased toxicity or lack of compliance.
Adding concomitant chemotherapy to altered fractionation is
a logical approach to improve survival in locally advanced head
and neck cancer patients, but it may be at the cost of higher tox-
icity. The more wide spread use of newer radiation techniques
like intensity modulated radiotherapy has helped to reduce
radiotherapy induced toxicity, thus making the addition of con-
current chemotherapy to altered fractionation easier.
Accelerated postoperative radiotherapy
Adjuvant radiation is often employed in locally advanced
HNSCC with adverse pathologic factors [25]. Awwad et al.
in an early trial of accelerated versus conventional fractiona-
tion radiation found no added impact. However, accelerated
78 S. Mallick et al.radiation was found to be associated with improved disease con-
trol in fast growing tumors [26]. Sanguineti et al. in an attempt
to evaluate accelerated adjuvant radiation randomly allocated
226 patients of locally advanced oral cavity, oropharynx, larynx,
or hypopharynx, with high-risk features (pT4, SM+, N2-3, PNI
+, LVI+, ECE+, subglottic extension) after surgery to either
conventional radiation 60 Gy in 30 fractions vs. accelerated radi-
ation 64 Gy over 5 weeks. The trial reported signiﬁcantly
increased conﬂuent mucositis 27% vs. 50% (SS) but similar late
toxicity 18% vs. 27% (NS). However, locoregional control was
not different in the two arms. Point should be made of a trend to
beneﬁt for patients with radiotherapy delay >7 weeks [27].
Another recent trial randomized 279 patients of high-risk SCC
larynx and oral cavity/oropharynx to receive conventional radi-
ation 63 Gy in 35 fractions over 7 weeks vs. accelerated radiation
63 Gy in 35 fractions over 5 weeks. At 3 years loco regional con-
trol was similar between two arms (64% vs. 70%). Conﬂuent
mucositis was higher in the accelerated radiation arm but late
toxicity was similar. In a planned subset analysis Locoregional
control advantage was found more for patients with primary
in oral cavity and oropharynx [28].Hypo fractionation
Hypo fractionated radiotherapy is practiced mostly in the pallia-
tive setting. There is no consensus regarding the optimum dose
and fraction schedule. Mohanti et al. evaluated 20 Gy in 5 frac-
tions palliative radiotherapy (PRT) for advanced head and neck
cancer patients followed by further radiation dose in responders
[29]. The patients were evaluated for response after 1 month and
responders (>50% objective response) were treated with further
radiation equivalent to 70 Gy. Symptom relief ranged from 47%
to 76% for pain, dysphagia and respiratory distress. The median
OS period of 200 days and 400 days (P= 0.001) for palliative
RT only and further radiotherapy groups, respectively. The
QUAD shot study evaluated 14 Gy in 4 fractions over 2 days
and repeated every 4 weeks for 3 sessions in palliative cases of
head and neck [30]. The study found median overall survival
of 5.7 months, median progression free survival 3.1 months.
The rationale behind hypo-fractionation in palliative
setting in head and neck cancers is the delivery of higherTable 4 Summary of trials using hypo-fractionation in laryngeal ca
Author/year Nature of trial Number
of
patients
Fraction size
Sung/2013[32] Phase III randomised
trial – T1–2 glottic
cancer
156 2.2 Gy per fra
Kumiko karasawa/
2013 [33]
Retrospective – T1
and T2 Laryngeal and
hypopharyngeal
cancers
80 2.2 Gy per fra
Rikiya Onimaru/
2010 [34]
Retrospective – T1
laryngeal
201 2.2 Gy per fra
Ana Cristina
Amado/2012 [35]
Retrospective – T1,
T2 laryngeal
27 2.2 Gy per frabiologically equivalent doses at shorter treatment duration,
but at the risk of higher late normal tissue toxicity. The various
trials that have evaluated the role of hypo fractionated pallia-
tive radiotherapy have found good response rate and good
relief of symptoms with this approach. This approach is also
suited in areas where there is a high burden of patients on
machines especially in developed countries. The long term tox-
icity may not be a major concern for these patients as they may
not survive that long for late toxicity to appear.
Mild hypo-fractionation is also gaining signiﬁcance in early
laryngeal cancers [31]. Sung et al. did a prospective phase III
trial in T1, 2 glottic carcinoma in which he randomized 156
patients into conventional fractionation arm (66 Gy/33 frac-
tions for T1 and 70 Gy/35 fractions for T2) vs. hypo-
fractionation arm (63 Gy/28 fractions for T1 and 67.5 Gy/30
fractions for T2) [32]. There was no increased toxicity in
hypo-fractionation arm. The 5-year local progression-free sur-
vival was 77.8% for conventional fractionation arm and
88.5% for hypo-fractionation arm (p= 0.213). Thus they con-
cluded that hypo-fractionation is not inferior to conventional
with a similar toxicity proﬁle, in T1, T2 glottic carcinoma.
Kumiko et al. also tried to evaluate the role of hypo-
fractionation in T1-2 laryngeal and hypo pharyngeal cancers
[33]. He treated 80 patients with T1 and T2 laryngeal or hypo
pharyngeal cancers with deﬁnitive radiotherapy with a fraction
size of 2.25 Gy. The 5-year local control rates in the entire
group, larynx T1, larynx T2 and hypopharynx T1 were
85.8%, 97.6%, 70.1% and 85.7%, respectively. They had con-
cluded than this approach improved local control in T1 laryn-
geal and hypo pharyngeal cases compared to historical control.
The treatment was well tolerated and there was no long term
grade II toxicity after a median follow-up of 47 months. Sum-
mary of various trials which used hypo-fractionation in laryn-
geal cancer is given in Table 4.
Thus mild hypo-fractionation may be beneﬁcial in early
laryngeal cancers and may help in achieving better local con-
trol. Properly powered randomized control trial will throw fur-
ther light in this regard.
In the recent years great concern has been expressed regard-
ing the realistic quality review of treatment practices, patient’s
acceptance, compliance and outcome as well as inherent differ-
ence in therapeutic response, in developing countries comparedrcinoma.
Local control Toxicity
ction 5-year local progression-free survival
was 77.8%-conventional
fractionation arm 88.5%-hypo-
fractionation arm
No diﬀerence in
toxicity compared
to conventional
arm
ction 5-year – larynx T1-97.6% larynx T2-
70.1% hypopharynx T1-85.7%
No grade II toxicity
ction 91.9–3 years 1 case of severe
laryngeal edema
that required
tracheotomy
89.8–5 years
ction At a median follow-time of
24.7 months – 100% local control
No – severe late
toxicity.
Altered fractionation radiotherapy in Head and neck squamous cell carcinoma 79to western patients [4]. The achievement of additional local
control as well as overall survival beneﬁt becomes costly
because of the doubling of acute toxicity. At the same time this
practice considerably increases the departmental workload. In
developing countries where radiotherapy facility is far away
from necessary this practice might not be very feasible.
Conclusion
The analysis of the altered fractionation schedules alone or in
combination gives an additional beneﬁt over the conventional
radiotherapy practice in terms of loco regional control as well
as overall survival. Hyper-fractionated radiotherapy may con-
fer equivalent results to concomitant chemoradiotherapy.
Accelerated radiotherapy alone may confer inferior results to
concomitant chemoradiotherapy, but may be safely combined
with chemotherapy with better radiotherapy techniques. The
increase in acute morbidity and increase in workload are prob-
lems associated with altered fractionation practice. In future
altered fractionation with targeted agents as well as
immunotherapy is expected to confer better tumor control
with limited acute and late normal tissue toxicity.
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